SILENCE THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.19 USD | +1.32% |
|
+1.51% | +27.75% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 22.15M 27.66M | Sales 2025 * | 36.37M 45.41M | Capitalization | 825M 1.03B |
|---|---|---|---|---|---|
| Net income 2024 * | -42M -52.45M | Net income 2025 * | -72M -89.91M | EV / Sales 2024 * | 33.1 x |
| Net cash position 2024 * | 91.29M 114M | Net cash position 2025 * | 82.95M 104M | EV / Sales 2025 * | 20.4 x |
| P/E ratio 2024 * |
-47.5
x | P/E ratio 2025 * |
-34.1
x | Employees | 109 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on Silence Therapeutics plc
More recommendations
More press releases
| 1 day | +1.32% | ||
| 1 week | +1.51% | ||
| Current month | +1.51% | ||
| 1 month | +4.92% | ||
| 3 months | +5.47% | ||
| 6 months | +126.43% | ||
| Current year | +27.75% |
1 week
21.07
22.69
1 month
19.4823.18
Current year
16.0127.72
1 year
4.8427.72
3 years
4.5535.00
5 years
4.5535.00
10 years
4.5535.00
| Managers | Title | Age | Since |
|---|---|---|---|
Craig Tooman
CEO | Chief Executive Officer | 58 | 21-01-05 |
| Director of Finance/CFO | 52 | 21-03-31 | |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Romano
CTO | Chief Tech/Sci/R&D Officer | 64 | 19-07-28 |
David Lemus
BRD | Director/Board Member | 61 | 18-06-20 |
Iain Ross
CHM | Chairman | 71 | 04-07-01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 22.19 | +1.32% | 87,830 |
| 24-05-06 | 21.9 | -0.41% | 47,051 |
| 24-05-03 | 21.99 | +3.24% | 438,749 |
| 24-05-02 | 21.3 | -0.56% | 67,578 |
| 24-05-01 | 21.42 | -2.01% | 86,828 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotes
Silence Therapeutics plc is a United Kingdom-based biotechnology company. The Company is focused on discovering and developing molecules incorporating short-interfering ribonucleic acid (siRNA) to inhibit the expression of target genes in the pathology of diseases with unmet medical need. Its siRNA molecules are designed to harness the body's natural mechanism of RNA interference (RNAi), by specifically binding to and degrading messenger RNA (mRNA), molecules that encode specific targeted disease-associated proteins in a cell. The Company's mRNAi GOLD (GalNAc Oligonucleotide Discovery) platform is a platform of precision-engineered medicines designed to target disease-associated genes in the liver. Its wholly owned product candidates include SLN360, for the unmet need in reducing cardiovascular risk in people born with high Lipoprotein (a) levels and SLN124, for rare hematological conditions, including thalassemia, myelodysplastic syndrome (MDS), and polycythemia vera (PV).
Sector
-
Calendar
2024-05-13
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
22.19
USD
Average target price
55.8
USD
Spread / Average Target
+151.46%
EPS Revisions
- Stock Market
- Equities
- SLN Stock